RaygadaJL,LevineDP, 2009.Methicillin-Resistant Staphylococcus aureus: A Growing Risk in the Hospital and in the Community,Am Health Drug Benefits 2 86 -95
IdreesF,JabeenK,KhanMS,ZafarA, 2009.Antimicrobial resistance profile of methicillin resistant Staphylococcus aureus from skin and soft tissue isolates,J Pak Med Assoc 59 266 -9
WangZ,CaoB,LiuYM,GuL,WangC, 2009.Investigation of the prevalence of patients co-colonized or infected with methicillinresistant Staphylococcus aureus and vancomycin-resistant enterococci in China: a hospital-based study,Chin Med J 122 1283 -8
RashidZ,FarzanaK,SattarA,MurtazaG, 2012.Prevalence of nasal Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in hospital personnel and associated risk factors,Acta Pol Pharm 69 985 -91
ShresthaB,PokhrelB,MohapatraT., 2009.Antibiotic susceptibility pattern of nosocomial isolates of Staphylococcus aureus in a tertiary care hospital,Nepal. J Nepal Med Assoc 48 234 -8
CastanheiraM,SaderHS,FarrellDJ,MendesRE,JonesRN, 2012.Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types,Antimicrob Agents Chemother 56 4779 -85
KollefMH, 2009.New antimicrobial agents for methicillin-resistant 'Staphylococcus aureus',Crit Care Resusc 11 282 -6
2014.M100-S24 performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement;, -
LaudanoJB, 2011.Ceftaroline fosamil: A new broad-spectrum cephalosporin,J Antimicrob Chemother 66 11 -18
FarrellDJ,CastanheiraM,MendesRE,SaderHS,JonesRN, 2012.Clinical infectious diseases, 55 206 -14
SantosPD,DavisA,JandourekA,SmithA,David FH, 2013.Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience,J Antimicrob Chemother 25 341 -46
FriedlandD,EckburgP,JandourekA,HanS,ThyeD,CritchleyI., 2010.Microbiological outcomes of 2 multicenter phase 3 clinical trials of ceftaroline in community-acquired bacterial pneumonia,Am J Respir Crit Care Med 181 5481 -
JacquelineC,CaillonJ,MabecqueLV,MiègevilleAF,HamelA,BugnonD, 2007.In vivo efficacy of ceftaroline (PPI-0903), A new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model,Antimicrob Agents Chemother 51 3397 -400
JacquelineC,CaillonJ,Le MabecqueV,MiegevilleAF,GeY,BiekD, 2009.In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus, cephalosporin, ceftaroline, against vancomycin-susceptible and-resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin,Antimicrob Agents Chemother 53 5300 -2
JacquelineC,CaillonJ,BatardE,Le MabecqueV,AmadorG,GeY, 2010.Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model,J Antimicrob Chemother 65 2264 -5
JacquelineC,AmadorG,CaillonJ,Le MabecqueV,BatardE,MiègevilleAF, 2010.Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis,J Antimicrob Chemother 65 1749 -52
JonesRN,FlammRK,SaderHS,StilwellMG, 2013.Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: Selecting potent surrogate beta-lactam markers to predict ceftaroline activity against clinically indicated species,Diagn Microbiol Infect Dis 75 89 -93
ClarkMP,AppelbaumPC,Kosowska-ShickK, 2011.Multistep resistance development studies of ceftaroline in gram-positive and negative bacteria,Antimicrob Agents Chemother 55 2344 -51
JacobsMR,GoodCE,WindauAR,BajaksouzianS,BiekD,CritchleyIA, 2010.Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States,Antimicrob Agents Chemother 54 2716 -9
BradleyJS,ByingtonCL,ShahSS,AlversonB,CarterER,HarrisonC, 2011.The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America,Clin Infect Dis 53 25 -76